Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen

Urology

Volumn 48, Issue 6 SUPPL., 1996, Pages 76-80

  Morgan, Ted O ^a   McLeod, David G ^a,c   Leifer, Eric S ^a   Murphy, Gerald P ^b   Moul, Judd W ^a,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NORTHWEST HOSPITAL   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

BIOPSY; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0030448713     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00615-2     Document Type: Article

References (23)

1. Catalona WJ, Smith DS, Ratliff TL, and Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948-954, 1993.
2. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, and Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147: 841-845, 1992.
3. Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA, and Mostofi FK: Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Cancer 72: 1701-1708, 1993 .
4. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46: 5-27, 1996.
5. Woolf SH: Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med 333: 1401-1405, 1995.
6. Walsh PC: Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med 119: 948-949, 1993.
7. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi, LR, Dalkin, BL, Waters WB, MacFarlane MT, and Southwick PC: Comparison of digital rectal exam and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 151: 1283-1290, 1994.
8. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, and Cooner WH: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147: 815-816, 1992.
9. Benson MC, Whang IS, Olsson CA, McMahon DJ, and Cooner WH: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821, 1992.
10. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, and Walsh PC: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
11. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
12. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DS, McLeod DG, and Moul JW: Age-specific reference ranges for prostate-specific antigen in Black men. N Engl J Med 335: 304-310, 1996.
13. Christensson A, Laurell CB, and Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194: 755-763, 1990.
14. 1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
15. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
16. Hanley JA, and McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36, 1982.
17. Hanley JA, and McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843, 1983.
18. Keetch DW, Catalona WJ, and Smith DS: Serial prostate biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151: 1571-1574, 1994.
19. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
20. Luderer AA, Chen Y, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, and Thiel R: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
21. Bazinet M, Karkiewicz PI, Aprikian AG, Trudel C, Aronson S, Nachabe M, Peloquin F, Dessureault J, Goyal M, Zheng W, Begin LR, Elhilali MM: Value of systematic transition zone biopsies in the early detection of prostate cancer. J Urol 155 : 605-606, 1996.
22. Keetch DW, and Catalona WJ: Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. J Urol 154: 1795-1797, 1995.
23. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lovgren T, and Lilja H: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154: 1090-1095, 1995.